BUZZ-Alnylam falls as heart drug trial data fails to impress

** Shares of drug developer Alnylam ALNY.O fall 12.9% to $250 premarket

** Co says its drug vutrisiran on top of tafamidis reduced deaths and cardiovascular events by 28% in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) during a late-stage trial

** When tested as a monotherapy, vutrisiran showed a -significant reduction of 30% in mortality - ALNY

** Shares of BridgeBio BBIO.O, which is developing a rival drug, rise 14%

** ATTR-CM is a disease where function of the heart muscles is restricted due to the accumulation of irregular proteins

** Up to last close, stock was up 50% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))